{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 37,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a Gantt-style chart to represent clinical trial progress.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/4",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Pipeline development status",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78cdbe86-c722-48fe-8fa0-cfcff7c8a2d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "1~25,000 represents estimated treatment candidates... 4 Market Authorisation Application (MAA) validated by the European Medicines Agency (EMA)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fa74546-4073-4639-b3d9-90d604015b21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Program, Research, Phase 1/2, Phase 3, Regulatory Review, Addressable Market, Geographic Rights",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e8fe397-68dc-4854-85c4-2f8069afd38d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Aeglea's Human Enzyme Therapies for Rare Metabolic Diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d97303a-cb32-460f-9846-9e74184b4781",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "9967964f-559b-431e-9cb0-2e9d8f8c399b",
      "evidence": "The slide contains a table/data with a program, research, phase 1/2, phase 3, regulatory review, addressable market, and geographic rights.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "60c7fe97-42e5-43f6-8647-42e4a391a356",
      "evidence": "Horizontal bars representing clinical trial phases",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}